Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
PolyMedix develops acute care products for drug resistant bacteria and acute cardiovascular disorders based on biomimetics – novel non-peptide small molecule drugs that mimic the activity of proteins. PolyMedix’s compounds are designed with a proprietary computational drug design technology licensed from the University of Pennsylvania, and are based on the work of Drs. William DeGrado, Michael Klein, and Gregory Tew. In acute cardiovascular disorders, the Company is developing an anticoagulant antagonist, a small molecule compound which can reverse the activity of both heparin and low molecular weight heparins. Among other indications, this compound will be developed as a replacement for protamine, currently the only agent approved to reverse heparin ( www.polymedix.com )
Polymedix Inc
3701 Market Street Ste 442
Philadelphia, Pennsylvania 19104
USA
Tel: (215) 966-6199